A

ABRAMS K.

Last name: ABRAMS K.

2017 (v1)

Publication

Metadata-only

Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): An open-label, phase II study

Gattorno M. Obici L. Cattalini M.

Objective: To evaluate the efficacy of canakinumab, a high-affinity human monoclonal anti-interleukin-1β antibody, in inducing complete or almost complete responses in patients with active tumour necrosis factor receptor-associated periodic syndrome (TRAPS). Methods: Twenty patients (aged 7-78 years) with active recurrent or chronic TRAPS were...

Uploaded on: April 14, 2023
2017 (v1)

Publication

Metadata-only

Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy

Brachat A. H. Grom A. A. Wulffraat N.

Background: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1β-mediated pathways. We sought to characterize the molecular response to canakinumab and evaluate potential markers of response using samples from two pivotal trials in systemic juvenile idiopathic arthritis (SJIA). Methods: Gene expression was...

Uploaded on: April 14, 2023